COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus

Research Support

Funding Opportunities

Title Description Expires Sort ascending Grant Number
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. This is the reissue of PAR 18-534 and has replaced PAR 18-534.

Expiration February 17, 2022

PAR-19-220
2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: LAMA2

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its detrimental consequences (e.g. fibrosis, seizures, contractures, respiratory function decline).

We also encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring LAMA2-CMD closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: αDG

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. In addition to the symptoms of muscle weakness, most forms of congenital α-dystroglycanopathy involve brain development defects which may express as cognitive impairment, seizures, or visual impairment. For affected individuals and their families, the search for solutions to manage the cognitive and neural complications of αDG is as important, if not more so than muscle weakness. For this reason, we strongly encourage proposals addressing cognitive and neural complications. For example, establishing 3D mini-brains to study the developmental defects and potential treatments.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its incapacitating consequences (e.g. cognitive impairment, seizures, vision, contractures, respiratory function decline).

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring αDG closer to Clinical Trial Readiness.

Up to 50,000 for two years

αDG
2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy

Purpose: Promote the discovery of underlying disease mechanisms and the preclinical development of potential therapies, as well as the clinical translation of those efforts. As cardiac issues are the most hunting fear for patients and families we are particularly interested in receiving applications focused on testing potential therapies for LMNA-related cardiac pathologies.

Areas of Interest: Including but not limited to, 1) unraveling pathways involved in skeletal muscle or cardiac muscle pathology, 2) identifying novel drug targets or gene therapies, and 3) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline, etc).

Up to $50,000 funding for Two years

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring LMNA-CMD closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: Collagen VI

Purpose: Promote the discovery of underlying disease mechanisms and the preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) understanding tissue-specific phenotypes, 3) unraveling pathways involved in disease, 4) identifying novel drug targets or gene therapies, and 5) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline).

Up to $50,000 for Two years

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring COL6-CMD closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: SELENON

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline).

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring SELENON-RM closer to Clinical Trial Readiness.

Field Initiated Projects Program (Development)

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Act).

In carrying out a development activity under a FI Projects development grant, a grantee must use knowledge and understanding gained from research to create materials, devices, systems, methods, measures, techniques, tools, prototypes, processes, or intervention protocols that are beneficial to the target population.

$200,000/yr for 36 months

HHS-2020-ACL-NIDILRR-IFDV-0374
Field Initiated Projects Program (Research)

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Act).

In carrying out a research activity under a FI Projects research grant, a grantee must identify one or more hypotheses or research questions and, based on the hypotheses or research questions identified, perform an intensive, systematic study directed toward producing (1) new scientific knowledge or (2) better understanding of the subject, problem studied, or body of knowledge.

$200,000/yr for 36months

HHS-2020-ACL-NIDILRR-IFRE-0373
Advanced Rehabilitation Research Training (ARRT) Program - Community Living and Participation Department of Health and Human Services Administration for Community Living

The purpose of NIDILRR’s ARRT program, which is funded through the Disability and Rehabilitation Research Projects and Centers Program, is to provide advanced research training and experience to individuals with doctorates, or similar advanced degrees, who have clinical or other relevant experience. ARRT projects train rehabilitation researchers, including researchers with disabilities, with particular attention to research areas that support the implementation and objectives of the Rehabilitation Act, and that improve the effectiveness of services authorized under the Rehabilitation Act. ARRT projects under this opportunity announcement must provide advanced research training to eligible individuals to enhance their capacity to conduct high-quality multidisciplinary disability and rehabilitation research to improve outcomes for individuals with disabilities in NIDILRR’s major domain of community living and participation.

$200,000 per year (60 months)

HHS-2020-ACL-NIDILRR-ARCP-0368
Advanced Rehabilitation Research Training (ARRT) Program - Health and Function Department of Health and Human Services Administration for Community Living

The purpose of NIDILRR’s ARRT program, which is funded through the Disability and Rehabilitation Research Projects and Centers Program, is to provide advanced research training and experience to individuals with doctorates, or similar advanced degrees, who have clinical or other relevant experience. ARRT projects train rehabilitation researchers, including researchers with disabilities, with particular attention to research areas that support the implementation and objectives of the Rehabilitation Act, and that improve the effectiveness of services authorized under the Rehabilitation Act. ARRT projects must provide advanced research training to eligible individuals to enhance their capacity to conduct high-quality multidisciplinary disability and rehabilitation research to improve outcomes for individuals with disabilities in NIDILRR’s major domain of health and function.

$200,000 per year (60 months)

HHS-2020-ACL-NIDILRR-ARHF-0369

Information for Researchers

DCC Funding Information

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers

Muscular Dystrophy Research Support from MDCC Member Organizations

2018 Supported Projects
2017 Supported Projects
2016 Supported Projects
2015 Supported Projects